Living Medical eTextbook - Osteoporosis - Projects In Knowledge - Fracture Prevention and Therapeutic Management Edition Table of Contents - Assessment of Fracture Risk Using FRAX<SUP>®</SUP> CME Information

This CME/CE activity has expired for credit.
Click here to view our current activities in Osteoporosis.

ACCME Disclaimer

Chapter 3 – Assessment of Fracture Risk Using FRAX^®

Contributing Editor
	Marjorie M. Luckey, MD Medical Director Osteoporosis Center Saint Barnabas Medical Center Livingston, New Jersey
top

Activity Goal
The goal of this CME/CE activity is to address gaps in competence and practice performance by:

Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
Providing updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, treatment regimen requirements for compliance, and their role in providing fracture prevention/reduction

Target Audience
This activity is designed for primary care physicians, including internists, family practitioners, gynecologists, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.

Learning Objectives

•	Compute the 10-year probability of fracture using FRAX for postmenopausal women and men age 50 years and older with low bone mass in order to identify those who are at high risk for fracture and would benefit from treatment.
•	Interpret FRAX results using clinical judgment coupled with knowledge of the National Osteoporosis Foundation’s treatment guidelines and the limitations and caveats associated with FRAX in order to make treatment decisions for patients with osteopenia.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge^® designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Information: Nurses
Projects In Knowledge^® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

This activity is approved for 1.20 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.

top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Marjorie M. Luckey, MD, has received consulting fees from Amgen and Novartis Pharmaceuticals Corporation; is on the speakers bureau for Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, Inc, and sanofi-aventis.

PLANNING COMMITTEE

Jeffrey P. Levine, MD, MPH, is on the speakers bureau of Merck & Co, Inc and Procter & Gamble; on the advisory board of Amgen Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, and Wyeth Pharmaceuticals. Dr. Levine will be referencing unlabeled/unapproved uses of drugs or products in his activities.

Marjorie M. Luckey, MD, is on the speakers bureau for Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis; has received consulting fees from Amgen, Inc and Novartis Pharmaceuticals Corporation.

Ethel S. Siris, MD, is on the speakers bureau for Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis; has received consulting fees from Amgen, Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Procter & Gamble, and sanofi-aventis.

Gloria A. Bachmann, MD, is a consultant for and has received grant/research support from Astellas Pharma Inc, Bayer Group, Bionovo Inc, Boehringer-Ingelheim GmbH, Boston Scientific Corporation, Covance Inc, Duramed Pharmaceuticals, Inc, Femme Pharma Inc, Glaxo Smith Kline, Inc, Hoffmann-La Roche Inc, Hormos Medical, Johnson and Johnson Services, Inc, Merck and Company, Inc, Novartis Pharmaceuticals Corporation, Novo Nordisk, Inc, Procter & Gamble, Inc, QuatRx Pharmaceuticals Co., Wyeth Pharmaceuticals Inc, and Xanodyne Pharmaceuticals, Inc.

Cheryl L. Lambing, MD, is on the advisory board of Amgen Inc.

E. Michael Lewiecki, MD, FACP, FACE, has received grant/research support from Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Procter & Gamble, and Teva Pharmaceuticals; is on the board of directors of International Society for Clinical Densitometry.

Nancy J. Nordenson, MT (ASCP), MFA has no significant relationships to disclose.

This activity will not include a discussion of any unlabeled or unapproved uses of drugs or devices.

Peer Reviewer has disclosed no significant relationships.

Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top

1892.03